Trial reportJournal of consulting and clinical psychology2016
Longitudinal findings from a randomized clinical trial of naltrexone for young adult heavy drinkers.
Trial report in Journal of consulting and clinical psychology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Genetically influenced externalizing and internalizing risk pathways as novel prevention targets.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Trial
- Within- and between-person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation.Alcoholism, clinical and experimental research · 2022Trial
- Reward drinking and naltrexone treatment response among young adult heavy drinkers.Addiction (Abingdon, England) · 2021Trial
- Drinking goals and attainment in a naltrexone trial of young adult heavy drinkers.Journal of consulting and clinical psychology · 2018Trial
- Urgency traits moderate daily relations between affect and drinking to intoxication among young adults.Drug and alcohol dependence · 2017Trial
- Delinquent Adolescents' Substance Use during Stay in Juvenile Correctional and Rehabilitation Center.Addiction & health · 2025Article
- The mediating role of competence, autonomy, and relatedness in the activation and maintenance of sports participation behavior.Scientific reports · 2024Article
- Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies.Current psychiatry reports · 2019Review
- Pharmacological Treatment of Youth Substance Use Disorders.Journal of child and adolescent psychopharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveBehavioral interventions for young adults show limited effects 1-year posttreatment. Few studies have examined the longitudinal outcomes of pharmacotherapy trials to reduce heavy drinking. This study examined the posttreatment, longitudinal effects of the first placebo-controlled trial of naltrexone in young adult heavy drinkers.
methodRandomized, double-blind, placebo-controlled, 8-week trial. Follow-up assessments at posttreatment (8 weeks [8W]), 3 months [3M], 6 months [6M], and 12 months [12M]). Participants were young adults ages 18-25 (N = 118) who reported ≥4 heavy drinking days in the prior 4 weeks. Outcomes were percent days heavy drinking (PHDD), percent days abstinent (PDA), and drinks per drinking day (DPDD).
resultsThere were no time effects on PHDD. Treatment improvements were maintained posttreatment. A main effect of time was found for PDA. Both conditions continued to increase PDA posttreatment. For DPDD, a Treatment ×Time interaction emerged. In the naltrexone condition, DPDD increased from 8W to 6M and decreased from 6M to 12M, resulting in no net change posttreatment. The placebo group had a nonsignificant decrease in DPDD. The result was a significant benefit of naltrexone at 8W but not 12M.
conclusionsParticipants showed improvements or no change on most outcomes over 1 year posttreatment. Naltrexone had significant benefits over placebo at 8W. Although differences among groups diminished during follow-up, overall effects were maintained. Behavioral monitoring during treatment may impact long-term outcomes more than a single intervention following discontinuation of active medication. (PsycINFO Database Record
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.